Welcome, Guest
Username: Password: Remember me
Cytori´s Platform applications
  • Page:
  • 1

TOPIC: Scleroderma - Spectacular

Scleroderma - Spectacular 06 Mar 2014 06:49 #1379

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 388
  • Thank you received: 196
Scleroderma is going to be a STAR indication for Cytori.

www.imcas.com/en/imcas2014/schedule/lecturealldays/id/9436/badge/sympo-or-live-demo-or-new-technologies

I particularly like the comment from the above link that is as follows :
"As far as the hands are concerned, the results were spectacular with a very rapid improvement of the vascularisation of the fingers and later of trophic disorders that allowed a functional enhancement and a better quality of life." :happy:

Scleroderma is a condition for which there is no efficient cure/treatment ........ until now. I am looking forward to hearing more about the expanded trial which was mentioned when the initial trial results were announced. The announcement of the details concerning the expanded scleroderma trial should trigger a substantial share price increase. Europe would/should be willing to cover reimbursement quite quickly for this indication. This would provide substantial validation, income and visibility for CYTX. :woohoo:

The French researchers are spreading the word and obviously starting to train others in their technique as per the Scleroderma Workshop (see below). Interesting to note that our own John Fraser will be presenting (goodonya!! - fellow Vic graduate) on cryopreservation of SVF, which surely will be related to feasibility of follow up injections after initial treatment.

www.plastie-aphm.fr/Evenements/Scleroderma-workshop/Program

Also nice to see mention of SCLERADEC II, a multicenter trial. Is this the 2nd stage trial to be funded by French government?.

No doubt that the data from SCLEREDAC II will be included in the STAR registry! :joy: What is the STAR registry????? 500 patients in a multicenter trial with protocals established by Cytori ........... but who will pay??? :whistle:

thestarregistry.com/

The very quick positive treatment effect with no adverse reactions in a non vital organ with substantial quality of life improvement is potentially a very powerful endorsement of ADRC and the Celution device. Scleroderma is a game changer.

Lots of questions however such as which sites will provide this treatment and what is the cost of this procedure? :KO:

The STAR registry needs to be made known to all the Scleroderma Forums. We need patient awareness to build interest, proof of concept, confirmation of benefit and finally reimbursement. It will happen! :vegas:
The following user(s) said Thank You: fas, Joncon63, joeycav11, myownhedgefund, d9dozrman, fatboy

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 06 Mar 2014 07:09 #1380

  • d9dozrman
  • d9dozrman's Avatar
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 151
  • Thank you received: 21
Spectacular finds, thank you for sharing! :vegas:

d9

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 06 Mar 2014 08:50 #1381

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Yes- that all sounds very impressive and the way to go.

At one point in time- insurers, be they private or semi-governmental- will start to reimburse and off we go.

Probably for a whole range of disorders- from the last announcement-

In the U.S., the Company is pursuing a clinical development strategy initially with the RECOVER trial. Internationally, the Company is in the process of initiating two multi-center registries for related indications in countries where the Celution® System is available for commercial use. The ACHILLES Registry will collect data from patients with muscle and ligament injuries treated with Cytori Cell Therapy and the RELIEVE Registry will collect data from patients with osteoarthritis. Both registries will collect patient data and may support future regulatory and reimbursement efforts.


Especially Osteoarthritis is pretty big- but cardiac and other vascular disorders probably will go the same "development route" :vegas:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Scleroderma - Spectacular 06 Mar 2014 19:55 #1385

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2861
  • Thank you received: 204
I cant remember if this article was ever posted or discussed but this appears how NOT to use autologus stem cells for scleroderma and seems Cytori's approach is they way to go although I still would wonder if a IV treatment of Cytori ADRC's wouldnt be of benefit.

www.medscape.com/viewarticle/765319

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 07 Mar 2014 10:07 #1386

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Hedge-

The link that you gave is-SC TRANSPLANT- i.e. nothing new but practiced for many years with high mortality rates, since first the marrow has to be killed with chemo first.

I believe in the future, some of the heavy cases will be treated with ADRCs by systemic IV delivery yes- but we aint there yet.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Scleroderma - Spectacular 07 Mar 2014 19:48 #1387

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2861
  • Thank you received: 204
Fas...yes, aware of the approach in the article...just showing how much simpler and better Cytori's approach is and would also like to see if a more systemic approach from Cytori would be even better beyond treating the hands.

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 03 Sep 2014 14:20 #2136

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 388
  • Thank you received: 196
New info on an indication that I believe is a sleeper, but which I believe may well be a catalyst for CYTX share price.

cbmt.fmbcfmba.ru/news/188/postreliz-konferentsii-innovatsionnye-metody-lecheniya-sklerodermii/

Admittedly Russian is not very familiar to me or most of us so the BING translation may be of some help:

" Report on the Conference "innovative treatments for Scleroderma" July 11, 2014 on the basis of the Federal Medical Center. the biophysical A.i. Burnazâna Fmba, a conference dedicated to innovative treatments for Scleroderma. The seminar brought together leading experts from RESEARCH INSTITUTE of Rheumatology. N.a. Nasonovoj WOUNDS, AFTER they First HBO GBOU. Medical Academy Of Russia, the MAIN STATE FMBC them. A.i. Burnazâna Fmba, Institute of human stem cells, as well as plastic surgeons and developers cell products (over 50 employees). The Conference discussed possibilities for the treatment of patients with Scleroderma using stromal′no-vascular fraction cells of adipose tissue. France's leading expert-Professor G.Magalon presented the results of pre-clinical tests and of clinical research SCLERADEC on evaluating the effectiveness and safety of the local introduction of vascular stromal′no cells of adipose tissue to treat sklerodaktilii. Professor g. Magalon told Conference participants about the prospects for further development of the method: the clinical research of SCLERADEC II, SCLERADEC III (treatment of systemic sclerosis), SCLERAFACE (treatment of patients with lesions of the skin).

Reports were presented on patofiziologičeskim fundamentals of therapy using stromal′no-vascular cell fractions of fatty tissue, a draft Russian Protocol clinical trial evaluating the efficacy and safety of subcutaneous injection stromal′no vascular fractions of fatty tissue in patients with sklerodaktiliej, world experience and prospects of clinical application of stromal′no vascular fraction cells of adipose tissue.

Great interest clinicians called training, held by Professor g. Magalon, which discussed the particular examination of patients with scleroderma, used techniques and tools.

In a separate set of reports were provided on the potential and prospects for the use of lipofilinga in clinical practice.

All participants took an active part in the discussion of the information provided, expressed their observations and comments.

Professor g. Magalon is also Chairman of the European society of Cell Society Europe, under whose auspices the biennial Professional Conference is held with the participation of leading specialists (an average of 1000-2000 people). Agreements have been reached on the formation of the MAIN STATE FMBC them. A.i. Burnazâna Fmba Russian Unit Cell of Society. Membership in the professional community offers the prospect of simplified filing publications in the leading European and American scientific journals, simplifies interaction with leading experts, including with the possibility of participation of employees in workshops, conferences and seminars, raised the status of the Centre on the international stage, makes it possible to hold the next event in the Russian Federation in autumn of the year 2015."

Seems that Guy Magalon is spreading the word ........... and there are keen listeners ......... and new developments of which we know nothing ????????

Professor g. Magalon told Conference participants about the prospects for further development of the method: the clinical research of SCLERADEC II, SCLERADEC III (treatment of systemic sclerosis), SCLERAFACE (treatment of patients with lesions of the skin).
The following user(s) said Thank You: d9dozrman, keysman

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 04 Sep 2014 07:37 #2138

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Yes John.

It seems that our Russian friends are pretty much excited about Celution and ADRCs as therapeutic for auto immune related disorders.

I just checked my search on the Burnasyan Biomedical Centre from which your Russian article comes and at least now we see that they also started a 12 patients clinic on Osteoarthritis. Record is from August 15 2014.

Burnasyan Clinicaltrials.gov search : Link here

So now we have Glaucoma, Urethral strictures and Osteoarthritis with Celution CRS and SUI with Puregraft at Burnasyan.

Just saying- a large shareholder of Okyanos told me that it is likely that they also will treat auro-immune disorders beyond cardiac patients.

Hedrick and his scientists have clearly missed the boat on auto immune.

Why am I not so surprised?????? :cry: :cry:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Scleroderma - Spectacular 05 Sep 2014 07:27 #2139

  • rongside
  • rongside's Avatar Topic Author
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 388
  • Thank you received: 196
For all their incompetence (todate) they did manage to secure exclusive rights to Medistem's patents relating to auto immune disease and "Stem Cell Mediated Treg Activation''

It would appear that the French at least are taking an active interest in Celution and Scleroderma. We knew that SCLEREDAC II was an expanded trial in sclerodactili. Who knows maybe CYTX will inform us about it !? What is really interesting is that they appear to be considering (treating) Systemic Sclerosis. :happy:

This opens up a whole range of systemic autoimmune diseases for which there is no cure .......... Lets hope that the Europeans make this a priority. Any positive news in autoimmune disease, in a rational world, would make the share price explode instead of imploding.

The current valuation is embarrassing. My next trade gets me to 100,000 shares. I never wanted this many, I certainly never thought I would be able to afford them ............. averaging down is not usually the smart thing to do :KO: time will tell :winky:
The following user(s) said Thank You: d9dozrman, keysman

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 05 Sep 2014 12:44 #2140

  • forgotmorthanuno
  • forgotmorthanuno's Avatar
  • Offline
  • Senior Boarder
  • Senior Boarder
  • Posts: 73
  • Thank you received: 44
There is no technical reason to buy here as the count is to zero.
We need to see 2 consecutive daily closes above 1.42
Next target is 4.05
I love the science ; I want to live the company. Any competent manager should make this dog hunt. We will see.
F
The following user(s) said Thank You: d9dozrman, keysman

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 05 Sep 2014 19:56 #2141

  • Wall Street Titan
  • Wall Street Titan's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 901
  • Thank you received: 148
Rongside, nice find. Just amazingly.frustrating how we know we have something that works, yet we are where we are. Mind boggling how all this has played out. How will Hedrick solve the balance sheet in a shareholder friendly way as is his stated goal? This is his first BIG test.

Please Log in or Create an account to join the conversation.

Scleroderma - Spectacular 06 Sep 2014 04:37 #2142

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116

For all their incompetence (todate) they did manage to secure exclusive rights to Medistem's patents relating to auto immune disease and "Stem Cell Mediated Treg Activation''


Yes- at least that is some consolation. Thomas Ichim (the inventor) has withdrawn himself from the social media and apparently devotes himself only to his president role at Regen BioPharma Inc.

From the past, when we exchanged quite some information, I know he said that he knew CC very well and he said he was looking to start an MS clinical trial with some ADRC extraction device. Could not finance that surely as MediStem.

To me- the potential of ADRCs for auto-immune always have been very very high and if you read a bit in the attached paper from 2009, you will understand that. I made investors also aware of this in my Newsletter (in 2011 I believe), but Cytori just did their thing and moved from one to the other strategy. My partner would say "from one cul-de-sac to another cul-de-sac".... :really: :sos:

Anyway- if you have some time - read the chapter 5 with the treated cases of patients with MS- highly astonishing and proven to be right by many MS patients treated at Cellmedicine Panama subsequent to the issue of this paper....


File Attachment:

File Name: FreshSVFADRCsforMS.pdf
File Size: 600 KB
Attachments:
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Scleroderma - Spectacular 06 Sep 2014 11:59 #2143

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
Just to finish up on the "chain of evidence" in regard of the superiority of SVF in auto-immune and MS in particular- the pre-clinical study of Gimble et al in a well-proven rodent model for MS.

Here- SVF was compared to stromal cells from fat and bone-marrow. Not the punch-less "over-cultured" cells, but the "normal" cultured material with max. 4 passages.

Here the "Gemisch" also had the most impressive results.

Introduction
While administration of ex vivo culture-expanded stem cells has been used to study immunosuppressive mechanisms in multiple models of autoimmune diseases, less is known about the uncultured, non-expanded stromal vascular fraction (SVF) based therapy. The SVF is composed of a heterogeneous population of cells and has been used clinically to treat acute and chronic diseases, alleviating symptoms in a range of tissues and organs.
Methods
In this study, the ability of human SVF cells was compared to culture expanded adipose stem cells (ASCs) and bone-derived marrow stromal cells (BMSCs) as a treatment of myelin oligodendrocyte glycoprotein (MOG)35-55 induced experimental autoimmune encephalitis (EAE) in C57Bl/6J mice, a well-studied multiple sclerosis model (MS). A total of 1 × 106 BMSCs, ASCs, or SVF cells were administered intraperitoneally concomitantly with the induction of disease. Mice were monitored daily for clinical signs of disease by three independent, blinded investigators and rated on a scale of 0 to 5. Spinal cords were obtained after euthanasia at day 30 and processed for histological staining using luxol fast blue (LFB), toluidine blue (TB), and hematoxylin and eosin (H&E) to measure myelin and infiltrating immune cells. Blood was collected from mice at day 30 and analyzed by ELISA to measure serum levels of inflammatory cytokines.
Results
The data indicate that the intraperitoneal administration of all cell types significantly ameliorates the severity of disease. Furthermore, the data also demonstrates, for the first time, that the SVF was as effective as the more commonly cultured BMSCs and ASCs in an MS model. All cell therapies also demonstrated a similar reduction in tissue damage, inflammatory infiltrates, and sera levels of IFNγ and IL-12. While IFNγ levels were reduced to comparable levels between treatment groups, levels of IL-12 were significantly lower in SVF-treated than BMSC-treated or ASC-treated mice.
Conclusions
Based on these data, it is evident that the SVF cells have relevant therapeutic potential in an animal model of chronic MS and might represent a valuable tool for stem cell-based therapy in chronic inflammatory disease of the CNS. SVF offers advantages of direct and rapid isolation procedure in a xenobiotic-free environment.


QED :bye:


File Attachment:

File Name: gimble-brunell-comp-pre-clinical-model-ms.pdf
File Size: 2,206 KB
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Scleroderma - Spectacular 07 Sep 2014 03:25 #2144

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3358
  • Thank you received: 1116
To conclude (at least from my side- comments from others of course are still very welcome)-

The "Hardcore" article which I wrote in 2012 and which can be found on this page, is still elementary on the issue. Here a lot of knowledge acquired from Thomas Ichim is used.

The Introduction to the paper from Riordan, Ichim had the following:

The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose
derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we
discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions.

The San Diego connection worked here- they had this from the Cytori ( or better Olympus-) study and also indicates strongly that the "fairy tales" from Hedrick in those days of wound healing capacities , were just that - Fairy Tales.

Still hopeful to find out some fine day, what Olympus did with the clinical data..... :whistle: :whistle:
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.111 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites